Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression
<h4>Background</h4> Although hyperuricemia is associated with chronic kidney disease, whether and how it should be managed for renoprotection remains debatable. Thus, we investigated whether allopurinol and febuxostat, the most frequently used urate-lowering treatments, have differential...
Main Authors: | Seokwoo Park, Jung Pyo Lee, Dong Ki Kim, Yon Su Kim, Chun Soo Lim |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884483/?tool=EBI |
Similar Items
-
Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease
by: Shankar Prasad Nagaraju, et al.
Published: (2023-01-01) -
Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
by: Zhimin Liao, et al.
Published: (2022-01-01) -
Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
by: Xudong Guan, et al.
Published: (2022-09-01) -
The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
by: Dong-Ryeol Ryu
Published: (2017-09-01) -
Febuxostat is superior to traditional urate-lowering agents in reducing the progression of kidney function in chronic kidney disease patients
by: Shuo-Chun Weng, et al.
Published: (2016-12-01)